Rigel Pharmaceuticals Reports Updated Phase 1b Data for R289 in Lower-Risk MDS Patients
I'm PortAI, I can summarize articles.
Rigel Pharmaceuticals announced updated Phase 1b data for R289, a dual IRAK1/4 inhibitor, in lower-risk myelodysplastic syndrome patients. The study, presented at the ASH Annual Meeting, shows R289 is well tolerated with preliminary efficacy at doses of 500 mg or more. 33% of transfusion-dependent patients achieved red blood cell transfusion independence. The study is ongoing, with a Phase 2 dose selection expected in the second half of 2026. R289 has Orphan Drug and Fast Track designations from the FDA.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments